Technical Analysis for CALC - CalciMedica, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | -1.37% | |
| Wide Bands | Range Expansion | -1.37% | |
| Gapped Up | Strength | -1.37% | |
| Crossed Above 20 DMA | Bullish | -2.61% | |
| Pocket Pivot | Bullish Swing Setup | -2.61% | |
| Earnings Movers | Other | -2.61% | |
| Wide Bands | Range Expansion | -2.61% | |
| Gapped Down | Weakness | -2.61% | |
| Fell Below 20 DMA | Bearish | 3.94% | |
| MACD Bearish Signal Line Cross | Bearish | 3.94% |
| Alert | Time |
|---|---|
| Down 1% | about 2 hours ago |
| Gap Up Partially Closed | about 23 hours ago |
| Rose Above Previous Day's High | about 23 hours ago |
| 10 DMA Resistance | about 23 hours ago |
| Gapped Up (Partial) | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/13/2024
CalciMedica, Inc. Description
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of calcium release-activated calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in four completed efficacy clinical trials. Auxora is in development for acute pancreatitis and asparaginase-associated pancreatitis. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Medication Inflammatory Diseases Abdominal Pain Pancreatitis Acute Pancreatitis Asparaginase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.59 |
| 52 Week Low | 1.0 |
| Average Volume | 20,848 |
| 200-Day Moving Average | 3.78 |
| 50-Day Moving Average | 4.65 |
| 20-Day Moving Average | 5.33 |
| 10-Day Moving Average | 5.60 |
| Average True Range | 0.44 |
| RSI (14) | 56.71 |
| ADX | 17.82 |
| +DI | 22.60 |
| -DI | 21.18 |
| Chandelier Exit (Long, 3 ATRs) | 4.94 |
| Chandelier Exit (Short, 3 ATRs) | 5.33 |
| Upper Bollinger Bands | 6.46 |
| Lower Bollinger Band | 4.20 |
| Percent B (%b) | 0.57 |
| BandWidth | 42.42 |
| MACD Line | 0.26 |
| MACD Signal Line | 0.31 |
| MACD Histogram | -0.0465 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.34 | ||||
| Resistance 3 (R3) | 6.34 | 6.05 | 6.19 | ||
| Resistance 2 (R2) | 6.05 | 5.84 | 6.05 | 6.15 | |
| Resistance 1 (R1) | 5.77 | 5.70 | 5.63 | 5.77 | 6.10 |
| Pivot Point | 5.48 | 5.48 | 5.41 | 5.48 | 5.48 |
| Support 1 (S1) | 5.20 | 5.27 | 5.05 | 5.19 | 4.86 |
| Support 2 (S2) | 4.91 | 5.13 | 4.91 | 4.81 | |
| Support 3 (S3) | 4.63 | 4.91 | 4.77 | ||
| Support 4 (S4) | 4.62 |
